IDNA vaccines and methods for using the same
AssigneeMedigen, Inc.
InventorsPeter Pushko, Igor Lukashevich
Life of this patent
Estimating the term…
Abstract
Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
Claims32
A vector comprising DNA encoding:
- (a) an infectious RNA molecule that encodes an alphavirus;
- and
- (b) a eukaryotic RNA polymerase promoter;
- wherein the DNA encoding the infectious RNA molecule is operably linked to the RNA polymerase promoter.
A vector comprising a DNA encoding:
- (a) an infectious RNA molecule that encodes a Venezuelan Equine Encephalitis (VEE) virus;
- and
- (b) a CMV promoter located 15(±3) nucleic acid residues upstream of the 5′ end of the DNA encoding the infectious RNA molecule;
- wherein the DNA encoding the infectious RNA molecule is operably linked to the CMV promoter.
A vector comprising a DNA encoding:
- (a) an infectious RNA molecule that encodes a Yellow Fever virus;
- and
- (b) a CMV promoter located from 15(±3) nucleic acid residues upstream of the 5′ end of the DNA encoding the infectious RNA molecule;
- wherein the DNA encoding the infectious RNA molecule is operably linked to the CMV promoter.
A human vaccine comprising a therapeutically effective amount of the a DNA vector encoding:
- (a) an infectious RNA molecule that encodes a nonpathogenic alphavirus or a nonpathogenic flavivirus;
- and
- (b) a CMV promoter located from 15(±3) nucleic acid residues upstream of the 5′ end of the DNA encoding the infectious RNA molecule;
- wherein the DNA encoding the infectious RNA molecule is operably linked to the CMV promoter, and the vaccine is pharmaceutically acceptable for a human.
A human vaccine comprising an effective amount of a DNA vector encoding:
- (a) an infectious RNA molecule that encodes a nonpathogenic flavivirus;
- and
- (b) a CMV promoter located from 15(±3) nucleic acid residues upstream of the 5′ end of the DNA encoding the infectious RNA molecule;
- wherein the DNA encoding the infectious RNA molecule is operably linked to the CMV promoter, and the vaccine is pharmaceutically acceptable for a human.
A vector comprising a DNA encoding:
- (a) an infectious RNA molecule, wherein
- (i) the RNA molecule encodes a non-pathogenic alphavirus;
- and
- (ii) the RNA molecule comprises a first 268 promoter and a second 26S promoter;
- and
- (b) a CMV promoter located from about 12 to about 18 nucleic acid residues upstream of the 5′ end of the DNA encoding the infectious RNA molecule.
Dependencies are inferred from the claim text.